Generic placeholder image

Current Pediatric Reviews

Editor-in-Chief

ISSN (Print): 1573-3963
ISSN (Online): 1875-6336

General Review Article

Erythema Infectiosum: A Narrative Review

Author(s): Alexander K. C. Leung*, Joseph M. Lam, Benjamin Barankin, Kin Fon Leong and Kam Lun Hon

Volume 20, Issue 4, 2024

Published on: 19 May, 2023

Page: [462 - 471] Pages: 10

DOI: 10.2174/1573396320666230428104619

Price: $65

Open Access Journals Promotions 2
conference banner
Abstract

Background: Erythema infectiosum occurs worldwide. School-aged children are most often affected. Since the diagnosis is mainly clinical, physicians should be well-versed in the clinical manifestations of erythema infectiosum to avoid misdiagnosis, unnecessary investigations, and mismanagement of the disease.

Objectives: The purpose of this article is to familiarize physicians with the wide spectrum of clinical manifestations and complications of erythema infectiosum associated with parvovirus B19 infection.

Methods: A search was conducted in July 2022 in PubMed Clinical Queries using the key terms "Erythema infectiosum" OR “Fifth disease” OR “Slapped cheek disease” OR “Parvovirus B19”. The search strategy included all clinical trials, observational studies, and reviews published within the past 10 years. Only papers published in the English literature were included in this review. The information retrieved from the above search was used in the compilation of the present article.

Results: Erythema infectiosum is a common exanthematous illness of childhood caused by parvovirus B19. Parvovirus B19 spreads mainly by respiratory tract secretions and, to a lesser extent, the saliva of infected individuals. Children between 4 and 10 years of age are most often affected. The incubation period is usually 4 to 14 days. Prodromal symptoms are usually mild and consist of lowgrade fever, headache, malaise, and myalgia. The rash typically evolves in 3 stages. The initial stage is an erythematous rash on the cheeks, with a characteristic “slapped cheek” appearance. In the second stage, the rash spreads concurrently or quickly to the trunk, extremities, and buttocks as diffuse macular erythema. The rash tends to be more intense on extensor surfaces. The palms and soles are typically spared. Central clearing of the rash results in a characteristic lacy or reticulated appearance. The rash usually resolves spontaneously within three weeks without sequelae. The third stage is characterized by evanescence and recrudescence. In adults, the rash is less pronounced than that in children and is often atypical. Only approximately 20% of affected adults have an erythematous rash on the face. In adults, the rash is more frequently found on the legs, followed by the trunk, and arms. A reticulated or lacy erythema is noted in 80% of cases which helps to distinguish erythema infectiosum from other exanthems. Pruritus is noted in approximately 50% of cases. The diagnosis is mainly clinical. The many manifestations of parvovirus B19 infection can pose a diagnostic challenge even to the best diagnostician. Complications include arthritis, arthralgia, and transient aplastic crisis. In most cases, treatment is symptomatic and supportive. When parvovirus B19 infection occurs in pregnant women, hydrops fetalis becomes a real concern.

Conclusion: Erythema infectiosum, the most common clinical manifestation of parvovirus B19 infection, is characterized by a “slapped cheek” appearance on the face and lacy exanthem on the trunk and extremities. Parvovirus B19 infection is associated with a wide spectrum of clinical manifestations. Physicians should be aware of potential complications and conditions associated with parvovirus B19 infection, especially in individuals who are immunocompromised, chronically anemic, or pregnant.

Keywords: Aplastic crisis, arthritis, erythema infectiosum, fifth disease, parvovirus B19, “slapped cheek” appearance.

Graphical Abstract
[1]
Macri A, Crane JS. ParvovirusesStatPearls. Treasure Island (FL): StatPearls Publishing 2022.
[2]
Mende M, Sockel K. Parvovirus B19 Infection. N Engl J Med 2018; 379(24): 2361.
[http://dx.doi.org/10.1056/NEJMicm1807156] [PMID: 30575471]
[3]
Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004; 350(6): 586-97.
[http://dx.doi.org/10.1056/NEJMra030840] [PMID: 14762186]
[4]
Magro CM, Dawood MR, Crowson AN. The cutaneous manifestations of humanparvovirus B19 infection. Hum Pathol 2000; 31(4): 488-97.
[http://dx.doi.org/10.1053/hp.2000.6714] [PMID: 10821497]
[5]
Rogo LD, Mokhtari-Azad T, Kabir MH, Rezaei F. Human parvovirus B19: A review. Acta Virol 2014; 58(3): 199-213.
[http://dx.doi.org/10.4149/av_2014_03_199] [PMID: 25283854]
[6]
Leung AK, Robson WL. Erythema infectiosum (fifth disease). Consultant Pediatrician 2006; 5: 366-70.
[http://dx.doi.org/10.25270/cfp.2006.06.00001]
[7]
Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975; 1(7898): 72-3.
[http://dx.doi.org/10.1016/S0140-6736(75)91074-0]
[8]
Landry ML. Parvovirus B19. Microbiol Spectr 2016; 4(3): 4-34.
[http://dx.doi.org/10.1128/microbiolspec.DMIH2-0008-2015] [PMID: 27337440]
[9]
Anderson MJ, Jones SE, Fisher-Hoch SP, et al. Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet 1983; 321(8338): 1378.
[http://dx.doi.org/10.1016/S0140-6736(83)92152-9] [PMID: 6134148]
[10]
Jordan JA. Treatment and prevention of parvovirus B19 infection. UpToDate, Inc 2022.
[11]
Koch WC. Fifth (human parvovirus) and sixth (herpesvirus 6) diseases. Curr Opin Infect Dis 2001; 14(3): 343-56.
[http://dx.doi.org/10.1097/00001432-200106000-00016] [PMID: 11964854]
[12]
Jordan JA. Virology, epidemiology, and pathogenesis of parvovirus B19 infection. UpToDate
[13]
Schwarz TF, Wiersbitzky S, Pambor M. Detection of parvovirus B19 in a skin biopsy of a patient with erythema infectiosum. J Med Virol 1994; 43(2): 171-4.
[http://dx.doi.org/10.1002/jmv.1890430214] [PMID: 8083666]
[14]
Takahashi Y, Murai C, Shibata S, et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA 1998; 95(14): 8227-32.
[http://dx.doi.org/10.1073/pnas.95.14.8227] [PMID: 9653169]
[15]
Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis 1985; 152(2): 257-65.
[http://dx.doi.org/10.1093/infdis/152.2.257] [PMID: 2993431]
[16]
Riley LE, Fernandes CJ. Parvovirus B19 infection during pregnancy. UpToDate
[17]
Huerta-Brogeras M, Avilés Izquierdo JA, Hernanz Hermosa JM, Lázaro-Ochaita P, Longo-Imedio MI. Petechial exanthem in “bathing trunk” distribution caused by parvovirus B19 infection. Pediatr Dermatol 2005; 22(5): 430-3.
[http://dx.doi.org/10.1111/j.1525-1470.2005.00109.x] [PMID: 16190994]
[18]
Young N, Mortimer P. Viruses and bone marrow failure. Blood 1984; 63(4): 729-37.
[http://dx.doi.org/10.1182/blood.V63.4.729.729] [PMID: 6322884]
[19]
Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: Cellular receptor for B19 parvovirus. Science 1993; 262(5130): 114-7.
[http://dx.doi.org/10.1126/science.8211117] [PMID: 8211117]
[20]
Jordan JA, DeLoia JA. Globoside expression within the human placenta. Placenta 1999; 20(1): 103-8.
[http://dx.doi.org/10.1053/plac.1998.0353] [PMID: 9950151]
[21]
Frydenberg A, Starr M. Slapped cheek disease. How it affects children and pregnant women. Aust Fam Physician 2003; 32(8): 589-92.
[PMID: 12973864]
[22]
Jordan JA. Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am J Obstet Gynecol 1996; 174(1): 37-42.
[http://dx.doi.org/10.1016/S0002-9378(96)70370-8] [PMID: 8572031]
[23]
Mandel ED. Erythema infectiosum: Recognizing the many faces of fifth disease. JAAPA 2009; 22(6): 42-6.
[http://dx.doi.org/10.1097/01720610-200906000-00009] [PMID: 19601449]
[24]
McOmish F, Yap PL, Jordan A, Hart H, Cohen BJ, Simmonds P. Detection of parvovirus B19 in donated blood: A model system for screening by polymerase chain reaction. J Clin Microbiol 1993; 31(2): 323-8.
[http://dx.doi.org/10.1128/jcm.31.2.323-328.1993] [PMID: 8432819]
[25]
Saldanha J, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: Implica-tions for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996; 93(3): 714-9.
[http://dx.doi.org/10.1046/j.1365-2141.1996.d01-1679.x] [PMID: 8652400]
[26]
Vafaie J, Schwartz RA. Erythema Infectiosum. J Cutan Med Surg 2005; 9(4): 159-61.
[http://dx.doi.org/10.1177/120347540500900401] [PMID: 16502203]
[27]
Yoto Y, Kudoh T, Haseyama K, et al. Incidence of human parvovirus B19 DNA detection in blood donors. Br J Haematol 1995; 91(4): 1017-8.
[http://dx.doi.org/10.1111/j.1365-2141.1995.tb05427.x] [PMID: 8547113]
[28]
Kostolansky S, Waymack JR. Erythema infectiosum. Treasure Island, FL: StatPearls Publishing. StatPearls 2021.
[29]
Ramdass P, Mullick S, Farber HF. Viral skin diseases. Prim Care 2015; 42(4): 517-67.
[http://dx.doi.org/10.1016/j.pop.2015.08.006] [PMID: 26612372]
[30]
Luo J, Zhang J, Lai W, et al. Disseminated human parvovirus B19 infection induced multiple organ dysfunction syndrome in an adult patient with alcoholic hepatitis complicated by hemolytic anemia: A case report and literature review. Front Immunol 2021; 12742990.
[http://dx.doi.org/10.3389/fimmu.2021.742990] [PMID: 34970255]
[31]
Prćić S, Gajinov Z, Zrnić B, Radulović A, Matić M, Djuran V. Epidemiological and clinical features of erythema infectiosum in children in Novi Sad from 2000 to 2009. Vojnosanit Pregl 2013; 70(12): 1081-4.
[http://dx.doi.org/10.2298/VSP110607026P] [PMID: 24450250]
[32]
Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B 19 in England and Wales. J Med Microbiol 1988; 25(2): 151-3.
[http://dx.doi.org/10.1099/00222615-25-2-151] [PMID: 3339634]
[33]
American Academy of Pediatrics. Parvovirus B19 (erythema infectiosum, fifth disease).Red Book: 2021-2024 Report of the Committee on Infectious Diseases. 32nd ed. Kimberlin DW, Barnett ED, Lynfield R, Swayer MH, Eds. Itasca, IL: American Academy of Pediatrics 2022; pp. 562-6.
[34]
Woolf AD, Campion GV, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989; 149(5): 1153-6.
[http://dx.doi.org/10.1001/archinte.1989.00390050111022] [PMID: 2541666]
[35]
Gillespie SM, Cartter ML, Asch S, et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA 1990; 263(15): 2061-5.
[http://dx.doi.org/10.1001/jama.1990.03440150069028] [PMID: 2157074]
[36]
Jordan JA. Clinical manifestations and diagnosis of parvovirus B19 infection. UpToDate
[37]
Weir E. Parvovirus B19 infection: Fifth disease and more. CMAJ 2005; 172(6): 743.
[http://dx.doi.org/10.1503/cmaj.045293] [PMID: 15767606]
[38]
Veraldi S, Rizzitelli G. Erythematous exanthem associated with primary infection by human parvovirus B19. Int J Dermatol 1995; 34(2): 119.
[http://dx.doi.org/10.1111/j.1365-4362.1995.tb03594.x] [PMID: 7737770]
[39]
Sachan D. Erythema infectiosum rash. Indian Pediatr 2011; 48(4): 338.
[PMID: 21532111]
[40]
Allmon A, Deane K, Martin KL. Common skin rashes in children. Am Fam Physician 2015; 92(3): 211-6.
[PMID: 26280141]
[41]
Mage V, Lipsker D, Barbarot S, et al. Different patterns of skin manifestations associated with parvovirus B19 primary infection in adults. J Am Acad Dermatol 2014; 71(1): 62-9.
[http://dx.doi.org/10.1016/j.jaad.2014.02.044] [PMID: 24726401]
[42]
Molenaar-de Backer MWA, Russcher A, Kroes ACM, Koppelman MHGM, Lanfermeijer M, Zaaijer HL. Detection of parvovirus B19 DNA in blood: Viruses or DNA remnants? J Clin Virol 2016; 84: 19-23.
[http://dx.doi.org/10.1016/j.jcv.2016.09.004] [PMID: 27664778]
[43]
Serjeant GR, Serjeant BE, Thomas PW, Anderson MJ, Patou G, Pattison JR. Human parvovirus infection in homozygous sickle cell disease. Lancet 1993; 341(8855): 1237-40.
[http://dx.doi.org/10.1016/0140-6736(93)91145-C] [PMID: 8098391]
[44]
Alcántara González J, Boixeda P, Truchuelo Díez MT, Fleta Asín B. Keratosis pilaris rubra and keratosis pilaris atrophicans faciei treated with pulsed dye laser: Report of 10 cases. J Eur Acad Dermatol Venereol 2011; 25(6): 710-4.
[http://dx.doi.org/10.1111/j.1468-3083.2010.03772.x] [PMID: 20569297]
[45]
Alexiades-Armenakas M. Tumid lupus erythematosus. Dermatol Online J 2001; 7(2): 14.
[http://dx.doi.org/10.5070/D31K03Z1TV] [PMID: 12165230]
[46]
Arias AF, Diaz A, Erdem G. Tinea faciei caused by Trichophyton benhamiae in a child. Pediatr Dermatol 2021; 38(2): 520-1.
[http://dx.doi.org/10.1111/pde.14486] [PMID: 33336837]
[47]
Callen J. Approach to the patient with facial erythema. UpToDate 2023.
[48]
Cox B, Levent F. Hand, foot, and mouth disease. JAMA 2018; 320(23): 2492.
[http://dx.doi.org/10.1001/jama.2018.17288] [PMID: 30561482]
[49]
Esposito S, Principi N. Hand, foot and mouth disease: Current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis 2018; 37(3): 391-8.
[http://dx.doi.org/10.1007/s10096-018-3206-x] [PMID: 29411190]
[50]
Grosshans EM. The red face: Erysipelas. Clin Dermatol 1993; 11(2): 307-13.
[http://dx.doi.org/10.1016/0738-081X(93)90067-M] [PMID: 8348445]
[51]
Jin H, Zhang G, Zhou Y, Chang C, Lu Q. Old lines tell new tales: Blaschko linear lupus erythematosis. Autoimmun Rev 2016; 15(4): 291-306.
[http://dx.doi.org/10.1016/j.autrev.2015.11.014] [PMID: 26678347]
[52]
Leung AKC, Rafaat M. Eruption associated with amoxicillin in a patient with infectious mononucleosis. Int J Dermatol 2003; 42(7): 553-5.
[http://dx.doi.org/10.1046/j.1365-4362.2003.01699_1.x] [PMID: 12839608]
[53]
Leung AKC, Kellner JD. Group A β-hemolytic streptococcal pharyngitis in children. Adv Ther 2004; 21(5): 277-87.
[http://dx.doi.org/10.1007/BF02850032] [PMID: 15727397]
[54]
Leung TNH, Hon KL, Leung AKC, Group A, Group A. Streptococcus disease in Hong Kong children: An overview. Hong Kong Med J 2018; 24(6): 593-601.
[http://dx.doi.org/10.12809/hkmj187275] [PMID: 30416105]
[55]
Leung AKC, Hon KL, Leong KF, Sergi CM. Measles: A disease often forgotten but not gone. Hong Kong Med J 2018; 24(5): 512-20.
[http://dx.doi.org/10.12809/hkmj187470] [PMID: 30245481]
[56]
Leung AKC, Hon KL, Leong KF. Rubella (German measles) revisited. Hong Kong Med J 2019; 25(2): 134-41.
[http://dx.doi.org/10.12809/hkmj187785] [PMID: 30967519]
[57]
Leung AKC, Lam JM, Alobaida S, Leong KF, Wong AHC. Juvenile dermatomyositis: Advances in pathogenesis, assessment, and management. Curr Pediatr Rev 2021; 17(4): 273-87.
[http://dx.doi.org/10.2174/1573396317666210426105045] [PMID: 33902423]
[58]
Leung AKC, Leong KF, Lam JM. Asymptomatic linear erythematous plaques following the lines of Blaschko on the cheek. Paediatr Child Health 2022; 27(3): 136-7.
[http://dx.doi.org/10.1093/pch/pxab113] [PMID: 35712038]
[59]
Lopez FA, Sanders CV. Fever and rash in the immunocompetent patient. UpToDate
[60]
Maliyar K, Abdulla SJ. Dermatology: How to manage rosacea in skin of colour. Drugs Context 2022; 11: 1-9.
[http://dx.doi.org/10.7573/dic.2021-11-1] [PMID: 35720055]
[61]
Papazoglou A, Mantadakis E. Fig tree leaves phytophotodermatitis. J Pediatr 2021; 239: 244-5.
[http://dx.doi.org/10.1016/j.jpeds.2021.08.029] [PMID: 34428434]
[62]
Rizzolo D, McWeeney M. A toddler’s fever and rash. JAAPA 2013; 26(7): 11-2.
[http://dx.doi.org/10.1097/01.JAA.0000431514.97948.fd] [PMID: 23923281]
[63]
Tsang V, Leung AKC, Lam JM. Cutaneous lupus erythematosus in children. Curr Pediatr Rev 2021; 17(2): 103-10.
[http://dx.doi.org/10.2174/1573396317666210224144416] [PMID: 33655840]
[64]
Cervero R. Systemic lupus erythematosus criteria nowadays. Med Clin 2022; 159(4): 187-8.
[http://dx.doi.org/10.1016/j.medcle.2022.04.008]
[65]
Lazar S, Kahlenberg JM. Systemic Lupus erythematosus: New diagnostic and therapeutic approaches. Annu Rev Med 2022; 74: 339-52.
[http://dx.doi.org/10.1146/annurev-med-043021-032611] [PMID: 35804480]
[66]
Rixe N, Tavarez MM. Serum sickness StatPearls. Treasure Island, FL: StatPearls Publishing 2022.
[67]
Sahba S, Huurnink A, Van den Berg JM, Tuitert B, Vastert SJ, Ten Tusscher GW. Systemic Juvenile Idiopathic Arthritis in two children; case report on clinical course, challenges in diagnosis and the role of FDG‐PET/CT‐scan. Clin Case Rep 2022; 10(6): e05900.
[http://dx.doi.org/10.1002/ccr3.5900] [PMID: 35734189]
[68]
Tjahjono L, Czaja R, Lalor L, Hasse-Rupp B, Wanat KA. Persistent papules and plaques in systemic juvenile idiopathic arthritis. Pediatr Dermatol 2022; 39(4): 616-8.
[http://dx.doi.org/10.1111/pde.15029] [PMID: 35560434]
[69]
Servey JT, Reamy BV, Hodge J. Clinical presentations of parvovirus B19 infection. Am Fam Physician 2007; 75(3): 373-6.
[PMID: 17304869]
[70]
Tello-Winniczuk N, Díaz-Jouanen E, Díaz-Borjón A. Parvovirus B19-associated arthritis: Report on a community outbreak. J Clin Rheumatol 2011; 17(8): 449-50.
[http://dx.doi.org/10.1097/RHU.0b013e31823abf1a] [PMID: 22089996]
[71]
Corcoran A, Doyle S. Advances in the biology, diagnosis and host–pathogen interactions of parvovirus B19. J Med Microbiol 2004; 53(6): 459-75.
[http://dx.doi.org/10.1099/jmm.0.05485-0] [PMID: 15150324]
[72]
Neely G, Cabrera R, Hojman L. Parvovirus B19: A DNA virus associated with multiple cutaneous manifestations. Rev Chilena Infectol 2018; 35(5): 518-30.
[http://dx.doi.org/10.4067/s0716-10182018000500518] [PMID: 30724999]
[73]
Scroggie DA, Carpenter MT, Cooper RI, Higgs JB. Parvovirus arthropathy outbreak in southwestern United States. J Rheumatol 2000; 27(10): 2444-8.
[PMID: 11036842]
[74]
Tiwari V, Bergman MJ. Viral arthritisStatPearls. Treasure Island, FL: StatPearls Publishing 2022.
[75]
Alexander V, Das S, Mangan A, Iyadurai R. Acute parvovirus B19 infection presenting as rheumatoid arthritis mimic. J Family Med Prim Care 2019; 8(3): 1257-9.
[http://dx.doi.org/10.4103/jfmpc.jfmpc_25_19] [PMID: 31041286]
[76]
Speyer I, Breedveld FC, Dijkmans BA. Human parvovirus B19 infection is not followed by inflammatory joint disease during long term follow-up. A retrospective study of 54 patients. Clin Exp Rheumatol 1998; 16(5): 576-8.
[PMID: 9779306]
[77]
Borsato ML, Bruniera P, Cusato MP, Spewien KE, Durigon EL, Toporovski J. Aplastic crisis in sickle cell anemia induced by parvovírus B19. J Pediatr 2000; 76(6): 458-60.
[http://dx.doi.org/10.2223/JPED.94] [PMID: 14647635]
[78]
Florea AV, Ionescu DN, Melhem MF. Parvovirus B19 infection in the immunocompromised host. Arch Pathol Lab Med 2007; 131(5): 799-804.
[http://dx.doi.org/10.5858/2007-131-799-PBIITI] [PMID: 17488170]
[79]
Grohall SJ, Colon AA, Churosh JL, Bryant R III, Zangwill SD. Parvovirus: From fifth disease to heart transplant. J Pediatr Health Care 2022; 36(2): 165-9.
[http://dx.doi.org/10.1016/j.pedhc.2021.05.006] [PMID: 34218967]
[80]
Barah F, Vallely PJ, Cleator GM, Kerr JR. Neurological manifestations of human parvovirus B19 infection. Rev Med Virol 2003; 13(3): 185-99.
[http://dx.doi.org/10.1002/rmv.388] [PMID: 12740833]
[81]
Boeck K, Mempel M, Schmidt T, Abeck D. Gianotti-Crosti syndrome: Clinical, serologic, and therapeutic data from nine children. Cutis 1998; 62(6): 271-4.
[PMID: 9878981]
[82]
Douvoyiannis M, Litman N, Goldman DL. Neurologic manifestations associated with parvovirus B19 infection. Clin Infect Dis 2009; 48(12): 1713-23.
[http://dx.doi.org/10.1086/599042] [PMID: 19441978]
[83]
Dubois A, Thellier S, Wierzbicka-Hainaut E, Pierre F, Anyfantakis V, Guillet G. Two cases of baboon-like exanthema in primary parvovi-rus B19 infection. Ann Dermatol Venereol 2010; 137(11): 709-12.
[http://dx.doi.org/10.1016/j.annder.2010.06.023] [PMID: 21074654]
[84]
Esmel-Vilomara R, Dolader P, Izquierdo-Blasco J, et al. Parvovirus B19 myocarditis in children: A diagnostic and therapeutic approach. Eur J Pediatr 2022; 181(5): 2045-53.
[http://dx.doi.org/10.1007/s00431-022-04406-x] [PMID: 35138467]
[85]
Ferrari B, Díaz MS, López M, Larralde M. Unusual skin manifestations associated with parvovirus B19 primary infection in children. Pediatr Dermatol 2018; 35(6): e341-4.
[http://dx.doi.org/10.1111/pde.13623] [PMID: 30230024]
[86]
Furukawa M, Kaji K, Masuda H, et al. Severe Aplastic anemia following parvovirus B19-associated acute hepatitis. Case Reports Hepatol 2017; 2017: 1-5.
[http://dx.doi.org/10.1155/2017/1359486] [PMID: 28512588]
[87]
Grilli R, Izquierdo MJ, Fariña MC, et al. Papular-purpuric “gloves and socks” syndrome: Polymerase chain reaction demonstration of parvovirus B19 DNA in cutaneous lesions and sera. J Am Acad Dermatol 1999; 41(5): 793-6.
[http://dx.doi.org/10.1016/S0190-9622(99)70027-7] [PMID: 10534650]
[88]
Hatakka A, Klein J, He R, Piper J, Tam E, Walkty A. Acute hepatitis as a manifestation of parvovirus B19 infection. J Clin Microbiol 2011; 49(9): 3422-4.
[http://dx.doi.org/10.1128/JCM.00575-11] [PMID: 21734024]
[89]
Kellermayer R, Faden H, Grossi M. Clinical presentation of parvovirus B19 infection in children with aplastic crisis. Pediatr Infect Dis J 2003; 22(12): 1100-1.
[http://dx.doi.org/10.1097/01.inf.0000101783.73240.4a] [PMID: 14688575]
[90]
Keramari S, Poutoglidis A, Chatzis S, Keramaris M, Savopoulos C, Kaiafa G. Parvovirus B19-associated myocarditis: A literature review of pediatric cases. Cureus 2022; 14(1): e21726.
[http://dx.doi.org/10.7759/cureus.21726] [PMID: 35251800]
[91]
Kishore J, Singh J. Detection of parvovirus B19 in a case of erythema infectiosum with myositis. Indian Pediatr 2006; 43(9): 814-7.
[PMID: 17033121]
[92]
Koliou M, Karaoli E, Soteriades ES, Pavlides S, Bashiardes S, Christodoulou C. Acute hepatitis and myositis associated with Erythema infectiosum by Parvovirus B19 in an adolescent. BMC Pediatr 2014; 14(1): 6.
[http://dx.doi.org/10.1186/1471-2431-14-6] [PMID: 24410941]
[93]
Kreuter A, Koushk Jalali B, Tigges C, Silling S, Lehmann P, Wieland U. Juvenile spring eruption associated with parvovirus B19 infection. JAMA Dermatol 2018; 154(11): 1356-7.
[http://dx.doi.org/10.1001/jamadermatol.2018.2932] [PMID: 30267044]
[94]
Kühl U, Rohde M, Lassner D, Gross UM, Escher F, Schultheiss HP. miRNA as activity markers in Parvo B19 associated heart disease. Herz 2012; 37(6): 637-43.
[http://dx.doi.org/10.1007/s00059-012-3656-3] [PMID: 22872003]
[95]
Leung AKC, Barankin B. Unilateral laterothoracic exanthem. J Pediatr 2015; 167(3): 775.
[http://dx.doi.org/10.1016/j.jpeds.2015.06.042] [PMID: 26187001]
[96]
Leventhal LJ, Naides SJ, Freundlich B. Fibromyalgia and parvovirus infection. Arthritis Rheum 1991; 34(10): 1319-24.
[http://dx.doi.org/10.1002/art.1780341018] [PMID: 1657005]
[97]
Naciute M, Mieliauskaite D, Rugiene R, et al. Frequency and significance of parvovirus B19 infection in patients with rheumatoid arthritis. J Gen Virol 2016; 97(12): 3302-12.
[http://dx.doi.org/10.1099/jgv.0.000621] [PMID: 27902343]
[98]
Pardi DS, Romero Y, Mertz LE, Douglas DD. Hepatitis-associated aplastic anemia and acute parvovirus B19 infection: A report of two cases and a review of the literature. Am J Gastroenterol 1998; 93(3): 468-70.
[http://dx.doi.org/10.1111/j.1572-0241.1998.468_1.x] [PMID: 9517662]
[99]
Pinho JRR, Alves VAF, Vieira AF, et al. Detection of human parvovirus B19 in a patient with hepatitis. Braz J Med Biol Res 2001; 34(9): 1131-8.
[http://dx.doi.org/10.1590/S0100-879X2001000900005] [PMID: 11514836]
[100]
Sequeira J, Calado A, Dias M, Manita M. Parvovirus B19 infection associated with hemolytic anemia and cranial polyneuropathy. J Neurovirol 2017; 23(5): 786-8.
[http://dx.doi.org/10.1007/s13365-017-0562-8] [PMID: 28831691]
[101]
Takeda S, Takaeda C, Takazakura E, Haratake J. Renal involvement induced by human parvovirus B19 infection. Nephron J 2001; 89(3): 280-5.
[http://dx.doi.org/10.1159/000046086] [PMID: 11598390]
[102]
Zou Q, Chen P, Chen J, et al. Multisystem involvement induced by human parvovirus B19 infection in a non-immunosuppressed adult: A case report. Front Med 2022; 9808205.
[http://dx.doi.org/10.3389/fmed.2022.808205] [PMID: 35492345]
[103]
Aktepe OC, Yetgin S, Olcay L, Özbek N. Human parvovirus B19 associated with idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 2004; 21(5): 421-6.
[http://dx.doi.org/10.1080/08880010490457141] [PMID: 15205085]
[104]
Heegaard ED, Eiskjaer H, Baandrup U, Hornsleth A. Parvovirus B19 infection associated with myocarditis following adult cardiac transplantation. Scand J Infect Dis 1998; 30(6): 607-9.
[http://dx.doi.org/10.1080/00365549850161188] [PMID: 10225391]
[105]
Finkel TH, Leung DYM, Harbeck RJ, et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: Opportunistic infection or aetiological agent? Lancet 1994; 343(8908): 1255-8.
[http://dx.doi.org/10.1016/S0140-6736(94)92152-0] [PMID: 7910276]
[106]
Waldman M, Marshall V, Whitby D, Kopp JB. Viruses and kidney disease: Beyond HIV. Semin Nephrol 2008; 28(6): 595-607.
[http://dx.doi.org/10.1016/j.semnephrol.2008.08.010] [PMID: 19013331]
[107]
Staroselsky A, Klieger-Grossmann C, Garcia-Bournissen F, Koren G. Exposure to fifth disease in pregnancy. Can Fam Physician 2009; 55(12): 1195-8.
[PMID: 20008596]
[108]
Anand A, Gray ES, Brown T, Clewley JP, Cohen BJ. Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med 1987; 316(4): 183-6.
[http://dx.doi.org/10.1056/NEJM198701223160403] [PMID: 3025725]
[109]
Kielaite D, Paliulyte V. Parvovirus (B19) infection during pregnancy: Possible effect on the course of pregnancy and rare fetal outcomes. A case report and literature review. Medicina 2022; 58(5): 664.
[http://dx.doi.org/10.3390/medicina58050664] [PMID: 35630081]
[110]
Kontomanolis EN, Fasoulakis Z. Hydrops fetalis and the Parvovirus B-19. Curr Pediatr Rev 2018; 14(4): 239-52.
[http://dx.doi.org/10.2174/1573396314666180820154340] [PMID: 30124157]
[111]
McCarter-Spaulding D. Parvovirus B19 in Pregnancy. J Obstet Gynecol Neonatal Nurs 2002; 31(1): 107-12.
[http://dx.doi.org/10.1111/j.1552-6909.2002.tb00029.x] [PMID: 11843014]
[112]
Petrikovsky BM, Baker D, Schneider E. Fetal hydrops secondary to human parvovirus infection in early pregnancy. Prenat Diagn 1996; 16(4): 342-4.
[http://dx.doi.org/10.1002/(SICI)1097-0223(199604)16:4<342:AID-PD851>3.0.CO;2-F] [PMID: 8734809]
[113]
Schwarz T, Roggendorf M, Hottenträger B, et al. Human parvovirus B19 infection in pregnancy. Lancet 1988; 332(8610): 566-7.
[http://dx.doi.org/10.1016/S0140-6736(88)92684-0] [PMID: 2900943]
[114]
Xu J, Raff TC, Muallem NS, Neubert AG. Hydrops fetalis secondary to parvovirus B19 infections. J Am Board Fam Med 2003; 16(1): 63-8.
[http://dx.doi.org/10.3122/jabfm.16.1.63] [PMID: 12583652]
[115]
Enders M, Weidner A, Zoellner I, Searle K, Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: Prospective evaluation of 1018 cases. Prenat Diagn 2004; 24(7): 513-8.
[http://dx.doi.org/10.1002/pd.940] [PMID: 15300741]
[116]
Riipinen A, Väisänen E, Nuutila M, et al. Parvovirus b19 infection in fetal deaths. Clin Infect Dis 2008; 47(12): 1519-25.
[http://dx.doi.org/10.1086/593190] [PMID: 18991512]
[117]
Barton LL, Lax D, Shehab ZM, Keith JC. Congenital cardiomyopathy associated with human parvovirus B19 infection. Am Heart J 1997; 133(1): 131-3.
[http://dx.doi.org/10.1016/S0002-8703(97)70259-X] [PMID: 9006302]
[118]
Bascietto F, Liberati M, Murgano D, et al. Outcome of fetuses with congenital parvovirus B19 infection: Systematic review and meta-analysis. Ultrasound Obstet Gynecol 2018; 52(5): 569-76.
[http://dx.doi.org/10.1002/uog.19092] [PMID: 29785793]
[119]
De Jong EP, Lindenburg IT, van Klink JM, et al. Intrauterine transfusion for parvovirus B19 infection: Long-term neurodevelopmental outcome. Am J Obstet Gynecol 2012; 206(3): 204.e1-5.
[http://dx.doi.org/10.1016/j.ajog.2011.12.035] [PMID: 22381602]
[120]
Katz V, McCoy M, Kuller J, Hansen W. An association between fetal parvovirus B19 infection and fetal anomalies: A report of two cases. Am J Perinatol 1996; 13(1): 43-5.
[http://dx.doi.org/10.1055/s-2007-994201] [PMID: 8645385]
[121]
Tiessen RG, van Elsacker-Niele AMW, Vermeij-Keers C, Oepkes D, van Roosmalen J, Gorsira MCB. A fetus with a parvovirus B19 infection and congenital anomalies. Prenat Diagn 1994; 14(3): 173-6.
[http://dx.doi.org/10.1002/pd.1970140305] [PMID: 8052564]
[122]
Weiland HT, Vermey-Keers C, Salimans MMM, Fleuren GJ, Verwey RA, Anderson MJ. Parvovirus B19 associated with fetal abnormality. Lancet 1987; 329(8534): 682-3.
[http://dx.doi.org/10.1016/S0140-6736(87)90442-9] [PMID: 2882099]
[123]
Ergaz Z, Ornoy A. Parvovirus B19 in pregnancy. Reprod Toxicol 2006; 21(4): 421-35.
[http://dx.doi.org/10.1016/j.reprotox.2005.01.006] [PMID: 16580942]
[124]
Kinney JS, Anderson LJ, Farrar J, et al. Risk of adverse outcomes of pregnancy after human parvovirus B19 infection. J Infect Dis 1988; 157(4): 663-7.
[http://dx.doi.org/10.1093/infdis/157.4.663] [PMID: 2831283]
[125]
Miller E, Fairley CK, Cohen BJ, Seng C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. BJOG 1998; 105(2): 174-8.
[http://dx.doi.org/10.1111/j.1471-0528.1998.tb10048.x] [PMID: 9501782]
[126]
Leung KKY, Hon KL, Yeung A, Leung AKC, Man E. Congenital infections in Hong Kong: An overview of TORCH. Hong Kong Med J 2020; 26(2): 127-38.
[http://dx.doi.org/10.12809/hkmj198287] [PMID: 32245914]
[127]
Hon KL, Leung KKY, Leung AKC, Man E, Ip P. Congenital infections in Hong Kong: Beyond TORCH. Hong Kong Med J 2020; 26(4): 318-22.
[http://dx.doi.org/10.12809/hkmj208398] [PMID: 32705996]
[128]
Revilla Grande AI, Carro García T, Sánchez de Dios M, Galán Calvo MJ, Nebreda Mayoral T. Outbreak of infectious erythema at a urban health center. Aten Primaria 2000; 26(3): 172-5.
[http://dx.doi.org/10.1016/S0212-6567(00)78636-7] [PMID: 10996951]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy